Indo US Bio-Tech Limited
Bombay Stock ExchangeTotal Valuation
Indo US Bio-Tech Limited carries a market capitalization of 1.79B, placing it among publicly traded companies globally. Its enterprise value stands at 2.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.79B |
| Enterprise Value | 2.27B |
Share Statistics
Indo US Bio-Tech Limited currently has 20.05M shares outstanding.
| Shares Outstanding | 20.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Indo US Bio-Tech Limited trades at a trailing price-to-earnings ratio of 14.98. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at 9.80.
| PE Ratio | 14.98 |
| PS Ratio | 1.78 |
| PB Ratio | 9.80 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Indo US Bio-Tech Limited trades at an EV/EBITDA multiple of 14.07 and an EV/FCF ratio of 107.19. The EV/Sales ratio of 2.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.07 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.05 |
| EV / EBITDA | 14.07 |
| EV / EBIT | 14.07 |
| EV / FCF | 107.19 |
Financial Position
Indo US Bio-Tech Limited maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.02, indicating elevated leverage, while an interest coverage ratio of 7.18 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.05 |
| Quick Ratio | 0.17 |
| Debt / Equity | 40.02 |
| Debt / EBITDA | 2.30 |
| Interest Coverage | 7.18 |
Financial Efficiency
Indo US Bio-Tech Limited posts a return on equity of 34.34 and a return on invested capital of 13.74.
| Return on Equity (ROE) | 34.34 |
| Return on Assets (ROA) | 11.36 |
| Return on Invested Capital (ROIC) | 13.74 |
| Return on Capital Employed (ROCE) | 23.75 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.94 |
Taxes
Over the trailing twelve months, Indo US Bio-Tech Limited has paid 7.97M in income taxes, reflecting an effective tax rate of 5.73.
| Income Tax | 7.97M |
| Effective Tax Rate | 5.73 |
Stock Price Statistics
Indo US Bio-Tech Limited's stock has declined approximately -42.10492% over the past 52 weeks. The 50-day moving average sits at 97.84, while the 200-day moving average is 117.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -42.10492% |
| 50-Day Moving Average | 97.84 |
| 200-Day Moving Average | 117.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Indo US Bio-Tech Limited generated 1.10B in revenue and converted that into 131.23M in net income, yielding earnings per share of 6.54. EBITDA reached 161.09M, while operating income came in at 161.09M.
| Revenue | 1.10B |
| Gross Profit | 301.69M |
| Operating Income | 161.09M |
| Pretax Income | 139.20M |
| Net Income | 131.23M |
| EBITDA | 161.09M |
| EBIT | 161.09M |
| Earnings Per Share (EPS) | 6.54 |
Balance Sheet
Indo US Bio-Tech Limited holds 69.13M in cash and equivalents against 370.36M in total debt, resulting in a net debt position of 309.13M. Total book value stands at 200.52M, with working capital of 811.69M providing operational flexibility.
| Cash & Cash Equivalents | 69.13M |
| Total Debt | 370.36M |
| Net Debt | 309.13M |
| Equity (Book Value) | 200.52M |
| Book Value Per Share | 9.99 |
| Working Capital | 811.69M |
Margins
Indo US Bio-Tech Limited operates with a gross margin of 27.32, reflecting its pricing power and cost economics. The operating margin of 14.59 and net profit margin of 11.88 provide insight into operational efficiency.
| Gross Margin | 27.32 |
| Operating Margin | 14.59 |
| Pretax Margin | 12.60 |
| Profit Margin | 11.88 |
| EBITDA Margin | 14.59 |
Stock Splits
Indo US Bio-Tech Limited's most recent stock split took place on August 29, 2023 with a 1:2 split ratio.
| Last Split Date | 8/29/2023 |
| Split Ratio | 1:2 |
Scores
Indo US Bio-Tech Limited posts an Altman Z-Score of 4.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.87 |